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Lisa Smart
School of Veterinary and Life Sciences, College of Veterinary Medicine, Murdoch University, Perth, WA, Australia
Background: Hemorrhagic shock and volume replacement can alter coagulation.
Synthetic colloids, hydroxyethyl starch (HES), and gelatin, may enhance
hypocoagulability. Our primary objective was to describe the effect of four fluid
products on coagulation in canine hemorrhagic shock. Our secondary objective was to
compare measurements of coagulation during shock to baseline in all dogs.
Methods: Anesthetized greyhounds subjected to atraumatic hemorrhage for 60min
were administered 20mL kg−1 of either fresh whole blood (FWB), 6% HES 130/0.4, 4%
succinylated gelatin (GELO), or 80mL kg−1 of isotonic crystalloid over 20min (n = 6
per group). Platelet closure time (PCT), rotational thromboelastometry (ROTEM) and
plasma coagulation assays were measured at baseline, end of hemorrhage (shock),
and 40 (T60), and 160 (T180) min after study fluid. ROTEM parameters included
clotting time (CT), clot formation time (CFT), alpha angle, maximum clot firmness (MCF),
lysis index at 60min (LI60), and thrombodynamic potential index (TPI) for INTEM,
EXTEM, FIBTEM (MCF only), and APTEM (LI60 only) profiles. Plasma coagulation assays
included prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen
concentration and activities of factor VII (FVII), factor VIII (FVIII), and von Willebrand
Factor antigen (vWF). Between-group differences were tested using linear mixed models
with post-hoc between-group comparisons (Bonferroni-Holm corrected). Differences
between baseline and shock were tested using paired t-tests. Significance was set at
P < 0.05.
Results: GELO showed longer PCT at T60, compared with FWB and CRYST,
and at T180, compared with all other groups. HES showed longer EXTEM
CT at T60, compared with all other groups. HES showed lower INTEM and
EXTEM MCF at T60 and lower INTEM MCF at T180, compared with FWB.
Some plasma coagulation assays showed greater hypocoagulability with HES.
Comparing shock to baseline, EXTEM CT, INTEM CFT, EXTEM CFT, PT, and FVIII
significantly increased and PCT, INTEM CT, INTEM MCF, EXTEM MCF, EXTEM LI60,
EXTEM TPI, FIBTEM MCF, APTT, fibrinogen, FVII, and vWF significantly decreased.
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Conclusions: In dogs with hemorrhagic shock, volume replacement with GELO caused
mild platelet dysfunction and HES was associated with coagulation changes consistent
with hypocoagulability, beyond effects of hemodilution. Shock alone produced some
evidence of hypocoagulability.
Keywords: hydroxyethyl starch, succinylated gelatin, crystalloid, freshwhole blood, platelet closure time, PFA-100,
rotational thromboelastometry (ROTEM), viscoelastic coagulation tests
INTRODUCTION
Hemorrhagic shock in dogs, due to traumatic, surgical, or
spontaneous hemorrhage, can result in organ dysfunction and
death (1–3). Hypocoagulability is a potential complication of
shock that can perpetuate hemorrhage. Clinical studies have
shown evidence of both hypocoagulability and hypercoagulability
in dogs experiencing hemorrhage (4–8), however results of
clinical studies can be difficult to interpret due to patient
heterogeneity and temporal variability of blood sampling in
relation to injury and treatment. There are limited experimental
studies examining coagulation during atraumatic hemorrhagic
shock in dogs, however, one study demonstrated decreased
platelet aggregation and mild hypocoagulability (9), while
another showed no significant change in platelet function (10).
Treatment of hemorrhagic shock includes restoration of
circulating blood volume by administration of intravenous
crystalloid fluids, synthetic colloid fluids, or blood products.
Synthetic colloids such as hydroxyethyl starch (HES) may be
chosen by veterinarians (11) due to their potentially superior
volume-expanding ability compared with crystalloids (12), as
well as their lower cost and greater availability compared with
blood products. However, some synthetic colloids have been
associated with hypocoagulability, which may increase risk of
bleeding in a patient already experiencing perturbed hemostasis.
In dogs, studies including in vitro (13–17), in vivo healthy dog
(18, 19), and experimental sepsis (20) designs have shown an
association between HES and both decreased platelet function
and hypocoagulability. Only one study has compared the effects
of low molecular weight (MW) HES with isotonic crystalloid
under the conditions of atraumatic hemorrhagic shock (10). This
study showed no difference in platelet function beyond the effects
of hemodilution, as measured by platelet closure time (PCT),
however other tests of coagulation were not performed. Given the
risk of potentiating hypocoagulability in clinical patients, further
information about the coagulation effects of HES administration
in dogs with hemorrhagic shock is needed.
Succinylated gelatins are a group of synthetic colloids that
are widely available in Europe and Australasia (11), and may
provide an alternative to HES products. However, there is
limited evidence for their safety profile, in both human and
veterinary medicine. Gelatin colloids have been associated with
hypocoagulability in humans both in vitro (21, 22) and in vivo
(23). In vitro dilution studies comparing gelatin to HES colloids
have shown greater hypocoagulability with HES (21, 22, 24),
suggesting gelatin may be the preferred colloid. The effects of
gelatin colloids on coagulation in dogs have not been thoroughly
investigated. One study showed decreased vonWillebrand Factor
antigen (vWF), platelet count and fibrinogen concentration
following oxypolygelatin administration to healthy dogs (25).
However, these changes may have been due to hemodilution, as
there was no crystalloid control.
Our study aimed to assess the effects of four
different intravenous fluid products on PCT, rotational
thromboelastometry (ROTEM), and plasma coagulation assays
in a canine experimental model of atraumatic hemorrhage
under general anesthesia. We compared the effects of 6% HES
130/0.4, 4% succinylated gelatin (GELO), fresh whole blood
(FWB) and balanced isotonic crystalloid (CRYST). In our study,
FWB served as a natural colloid comparison and CRYST served
as a hemodilution comparison. We hypothesized that volume
replacement with HES or GELO would result in the longest
PCT and most marked evidence of hypocoagulability, followed
by CRYST, then FWB. As a secondary exploratory objective,
we compared the effects of hemorrhagic shock alone on the
above measures of coagulation in all subjects. We hypothesized
that hemorrhagic shock, prior to fluid resuscitation, would be
associated with decreased PCT and hypocoagulability.
MATERIALS AND METHODS
Animals
This study was carried out in accordance with the
recommendations of the Australian Code for the Care and
Use of Animals for Scientific Purposes. The protocol was
approved by the Murdoch University Animal Ethics Committee
(R2666/14). This work represents part of a larger study that also
included assessment of glycocalyx shedding and inflammation
(26), and acute kidney injury after fluid resuscitation. Ex-
racing greyhounds that were unable to be rehomed were used.
Dogs were deemed healthy based on assessment of physical
examination, basic clinicopathologic parameters (packed cell
volume (PCV), total plasma protein, platelet count, urinalysis),
and ultrasound of the kidneys and urinary bladder. In accordance
with animal ethics requirements, blood removed during the
experiment that was not re-infused was made available to a
veterinary hospital blood bank, therefore blood bank stock levels
influenced study fluid allocation and precluded randomization.
Dogs were housed overnight in a kennel environment with free
access to water before the day of the experiment.
Anesthesia and Instrumentation
Dogs were premedicated with 0.3mg kg−1 methadone IM. Thirty
minutes later, anesthesia was induced with alfaxalone, titrated
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up to 3mg kg−1 via a cephalic venous cannula. Dogs were
orotracheally intubated and anesthesia was maintained with
isoflurane delivered by a rebreathing system, titrated to achieve
an end-tidal concentration of 1.4%. Dogs were mechanically
ventilated with a 0.3 fraction of inspired oxygen concentration,
with ventilation rate adjusted before baseline measurements to
achieve an end-tidal carbon dioxide partial pressure of 35–40
mmHg. Body temperature was monitored via an esophageal
thermistor probe and was maintained between 36 and 38◦C
by a heating mat and warmed air delivery system. Infusions
of compound sodium lactate (CSL) at 10mL kg−1 hr−1 and
fentanyl at 2 µg kg−1 hr−1 were administered IV throughout the
experiment, with the exception of suspending CSL during study
fluid infusion. Heart rate, arterial blood pressure, pulse oximetry,
end-tidal carbon dioxide and isoflurane, body temperature, and
anesthetic depth (eye position, facial reflexes, and jaw tone)
were monitored continuously and recorded at 5-min intervals
throughout anesthesia.
Instrumentation was performed with the dogs positioned
in left lateral recumbency. Percutaneous 0.5% bupivacaine
was instilled adjacent to the femoral nerve via ultrasound
guidance and a 14G, 88mm cannula was inserted into the
femoral artery after surgical exposure. This cannula was used
for continuous arterial pressure monitoring, arterial blood
sampling, and blood removal during the shock phase. A 14G,
133mm cannula was inserted percutaneously into the distal right
jugular vein and advanced to terminate between the thoracic
inlet and right atrium. This cannula was used for continuous
central venous pressure monitoring, venous blood sampling,
and study fluid administration. A urethral Foley catheter was
placed for urine output monitoring and to collect samples for
the acute kidney injury arm of the project. At the end of
instrumentation, dogs were repositioned in dorsal recumbency.
Blood pressure transducers were positioned at the approximate
level of the heart base (scapulohumeral joint) and calibrated to
atmospheric pressure. After repositioning and prior to baseline
data collection, if mean arterial blood pressure (MAP) decreased
to <60 mmHg for longer than 10min, up to 10mL kg−1 of CSL
was infused until MAP increased to >60 mmHg. A minimum of
10min elapsed after fluid infusion before baseline data and blood
samples were collected.
Experimental Procedure
The experimental design is summarized in Figure 1. Baseline
data and samples were collected immediately before blood
removal, which was achieved by passive flow from the femoral
arterial catheter into blood collection bags, containing citrate-
phosphate-dextrose-adenine anticoagulant. Once a MAP of 50
mmHg was reached, blood flow into collection bags was stopped.
Blood was then intermittently removed via a 60mL syringe to
maintain MAP of 50–60 mmHg for 60min. The total volume
of blood removed was calculated from change in weight of
collection bags and volume removed by syringe. Blood collection
bags were stored at room temperature until they were either
re-infused into the dog (FWB group) or transferred to the blood
bank.
At the end of the 60-min hypotension phase (shock), dogs
were administered one of four study fluids IV over 20min
including; 20mL kg−1 of autologous FWB, balanced HES 130/0.4
(Volulyte 6%, Fresenius Kabi) or GELO (Gelofusine, B. Braun
Medical), or 80mL kg−1 of CRYST (Plasmalyte-148, Baxter
Healthcare) (n = 6, per group). Previous work has shown that
these volumes of crystalloid and HES given to greyhounds in
hemorrhagic shock have produced similar effects on oxygen
extraction ratio and levels of hemodilution within 60min of
bolus (27). Dogs were then monitored for a further 3 h before
euthanasia with IV pentobarbitone 150mg kg−1. Cadavers were
retained for other teaching and research purposes within the
university.
Data Measurement and Sample Collection
Cardiovascular variables (heart rate, arterial and central venous
pressure, pulse pressure variation, and cardiac output) were
recorded at baseline, after 60min of hypotension (shock), and
then 40 (T60) and 160 (T180) min after the end of fluid
administration (Figure 1). Cardiac output was measured by the
lithium dilution technique, as previously described (27). Arterial
and venous blood samples were collected for measurement
of coagulation parameters, blood gas, electrolytes, lactate, and
hemoglobin at the same time points. Blood samples for blood
gas, electrolytes, and lactate were collected anaerobically into
heparinized syringes and stored on ice until analysis within
10min. Calculated variables included body surface area and
oxygen extraction ratio, using equations previously described
(27).
Coagulation Parameters
Blood for PCT, ROTEM, and plasma coagulation assays
was collected by syringe from the femoral arterial cannula
and transferred into blood tubes containing 3.2% buffered
sodium citrate with an anticoagulant:blood ratio of 1:9 (final
concentration 10.8mM citrate). Tubes were gently agitated to
ensure evenmixing of anticoagulant. Blood for PCT and ROTEM
was stored at room temperature until analysis. Blood for plasma
coagulation assays was stored on ice for<1 h, centrifuged at 1,350
× g for 10min, the supernatant separated into aliquots and then
stored at−80◦C for later batched analysis.
Platelet closure time was measured in duplicate within
10min of sample collection using the Platelet Function
Analyzer-100 (Dade Boehring Inc.) and collagen and adenosine
diphosphate cartridges, as previously described (10). Analysis
was immediately repeated if the coefficient of variation was
>15%. Platelet count was estimated on Diff-Quik stained smears
by manually counting platelets in 10 high-power fields and
multiplying the average number of platelets per field by 15 to
convert to× 109 L−1.
Rotational thromboelastometry (ROTEM R© delta, Tem
International GmbH) was performed according to the
manufacturer’s instructions and PROVETS guidelines (28)
using the INTEM (star-TEM and in-TEM reagents), EXTEM
(star-TEM and r ex-TEM reagents), FIBTEM (r ex-TEM and
fib-TEM reagents), and APTEM (r ex-TEM and ap-TEM
reagents) profiles. Measurement was started 30min after sample
collection. Each profile was run for at least 1 h following
initiation. Data recorded for the INTEM and EXTEM profiles
included clotting time (CT), clot formation time (CFT), alpha
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FIGURE 1 | Summary of experimental design.
angle (α), maximum clot firmness (MCF), and lysis index
at 60min (LI60). Thrombodynamic potential index (TPI)
was recorded for the EXTEM profile as a measure of global
coagulation (29), calculated using the equations:
TPI = EMX/CFT,
EMX = (100∗MCF)/(100−MCF).
Data recorded for the FIBTEM profile included MCF.
Hypocoagulability was defined as at least one of: prolonged
CT or CFT, reduced α, MCF, or TPI. Hypercoagulability was
defined as at least one of: shortened CT or CFT, elevated α,
MCF or TPI. Hyperfibrinolysis was assessed by comparing
the EXTEM and APTEM profiles and scored with a novel
(unvalidated) system, assigning samples to one of four categories
based on the authors’ interpretation: no hyperfibrinolysis,
defined as LI60 >90% on both EXTEM and APTEM; reversible
hyperfibrinolysis, defined as LI60 <90% on EXTEM and >90%
on APTEM; irreversible hyperfibrinolysis, defined as LI60 <90%
on both EXTEM and APTEM; and paradoxical increase in
hyperfibrinolysis, defined as LI60 >90% on EXTEM and <90%
on APTEM.
Plasma coagulation assays, including prothrombin time
(PT), activated partial thromboplastin time (APTT), fibrinogen
concentration, activity of factor VII (FVII) and factor VIII
(FVIII), and vWF, were performed using a commercial
coagulation analyser (ACLTop 300, BeckmanCoulter). All assays
were performed according to the manufacturer’s instructions.
Commercially-available human factor-deficient plasma was used
for the measurement of FVII and FVIII. Results of FVII, FVIII,
and vWF were compared with a pooled sample of all baseline
plasma from dogs in this study.
Statistical Methods
Visualization of histograms was used to confirm normal
distributions of continuous data, including baseline
characteristics, cardiovascular parameters and coagulation
parameters, and are summarized as mean (95% confidence
interval). Analysis of differences in baseline characteristics
and cardiovascular data between groups has been previously
described (26). Differences between groups in variables
measured over time were tested using mixed effect linear models.
Significant time-treatment interactions prompted post-hoc
between-group comparison of least-square means. Differences
in the frequency of hyperfibrinolysis scores between groups were
tested using Fisher’s exact test. Differences between baseline and
shock in all dogs, as per the secondary objective of this study,
were tested using paired Student’s t-tests. Significance was set
at P ≤ 0.05. Post-hoc pairwise comparisons were considered
significant against a Bonferroni–Holm adjusted significance level
to control for Type I error (30). Data were analyzed using SAS
Version 9.4 (SAS Institute).
RESULTS
Baseline and Cardiovascular Data
Twenty-seven ex-racing greyhounds (23 male, 4 female) were
used. Three dogs (2 male, 1 female) were excluded due to
equipment malfunction at the start of, or during, the experiment,
and data is presented for the remaining 24. Baseline and
cardiovascular parameters have been previously reported (26)
and only major findings are summarized below. There were
no significant between-group differences in age (all dogs,
range 1.6–4.0 years), sex, body weight (all dogs, range 27.7–
35.0 kg), body surface area (all dogs, range 0.93–1.13 m2), blood
volume removed (all dogs, range 35–66mL kg−1), or baseline
cardiovascular parameters. Two dogs received additional CSL
for hypotension prior to baseline: 6.8mL kg−1, GELO group
and 2.2mL kg−1, CRYST group. There were some differences
in measures of shock between groups directly after fluid
administration, but these differences resolved by T60. The only
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differences in hemoglobin were between the FWB group and all
other groups, as expected (26).
Comparisons Between Fluid Groups
There were no differences between groups in any coagulation
parameters at baseline or shock (all P > 0.05). Several between-
group differences were found after fluid administration.
There was evidence of platelet dysfunction in the GELO group
(Table 1). Platelet closure time was longer at T60 in the GELO
group, compared with FWB (P < 0.001) and CRYST (p= 0.003).
Platelet closure time was also longer at T180 in the GELO group,
compared with all other groups (HES P= 0.001, FWB P < 0.001,
CRYST P < 0.001). There were no significant differences between
any of the groups in estimated platelet count.
Rotational thromboelastometry showed some evidence of
hypocoagulability in the HES group (Table 2). INTEMMCF was
lower with HES at T60 (P = 0.002) and T180 (P = 0.008),
compared with FWB. EXTEM CT was longer at T60 in the HES
group, compared with all other groups (FWB P < 0.001, CRYST
P = 0.002, GELO P = 0.004). EXTEM MCF was lower at T60
in the HES group, compared with FWB (P < 0.001). Otherwise,
there were no significant differences in ROTEM parameters
between any of the groups. No between-group differences were
detected in hyperfibrinolysis scores (Table 3).
Plasma coagulation assays showed evidence of
hypocoagulability in all other groups compared with FWB,
with some evidence of greater hypocoagulability in the HES
group (Table 4). PT was shorter in the FWB group, compared
with all other groups, at T60 (all P < 0.001) and T180 (CRYST
P= 0.002, HES P= 0.001, GELO P= 0.004). PT was also shorter
in the GELO group at T60, compared with HES (P = 0.011).
APTT was shorter in the FWB group at T60, compared with all
other groups (all P < 0.001), and at T180, compared with HES
(P = 0.002). APTT was also shorter in the GELO group at T60,
compared with HES (P = 0.005). Fibrinogen concentration was
higher in the FWB group at T60, compared with all other groups
(CRYST P < 0.001, HES P < 0.001, GELO P = 0.012). FVII was
higher in the FWB group at T60, compared with all other groups
(CRYST P = 0.002, HES P < 0.001, GELO P < 0.001), and at
T180, compared with HES (P = 0.005) and GELO (P = 0.009).
FVIII was higher in the FWB group at T60, compared with all
other groups (all P < 0.001). vWF was higher in the FWB group
at T60, compared with all other groups (CRYST P < 0.001, HES
P = 0.002, GELO P = 0.007).
Comparisons Between Baseline and Shock
(All Dogs)
For the secondary objective, hemorrhagic shock was associated
with platelet activation and several markers of hypocoagulability,
compared with baseline (Table 5). There was a significantly
shorter PCT, with no significant difference in platelet count.
Evidence of hypocoagulability on ROTEM included significantly
longer EXTEM CT, INTEM CFT, and EXTEM CFT, and
significantly lower INTEM MCF, EXTEM MCF, FIBTEM MCF,
and EXTEM TPI. Conversely, there was significantly shorter
INTEM CT. There was also evidence of hyperfibrinolysis,
with significantly lower EXTEM LI60. There was a significant
difference in frequencies of hyperfibrinolysis scores between
baseline and shock (P = 0.0145). At baseline, 23 dogs showed no
hyperfibrinolysis and 1 showed irreversible hyperfibrinolysis; at
shock, 15 dogs showed no hyperfibrinolysis, 4 showed reversible
hyperfibrinolysis, 4 showed irreversible hyperfibrinolysis, and
1 showed paradoxical increase in hyperfibrinolysis. Evidence
of hypocoagulability on plasma coagulation assays included
significantly longer PT and significantly lower fibrinogen
concentration, FVII and vWF. Conversely, there was significantly
shorter APTT and significantly higher FVIII.
DISCUSSION
The main finding of our study was evidence of enhanced
hypocoagulability with administration of HES, compared with
GELO, FWB, and CRYST, as indicated by multiple ROTEM
parameters and plasma coagulation assays. Additionally, GELO
administration significantly impaired platelet function, as
measured by PCT, compared with all other fluid groups. These
TABLE 1 | Platelet closure time and count (mean, 95% confidence interval) in dogs (n = 6 per group) with hemorrhagic shock given 20mL kg−1 of either fresh whole
blood (FWB), hydroxyethyl starch 130/0.4 (HES), 4% succinylated gelatin (GELO), or 80mL kg−1 of balanced isotonic crystalloid (CRYST).
Parameter Baseline Shock T60 T180
PLATELET CLOSURE TIME (SEC)
FWB 79.2 (65.5–92.8) 65.7 (54.7–76.6) 72.7 (64.1–81.3)# 73.3 (63.7–83.0)#
CRYST 92.9 (75.5–110.4) 72.6 (61.7–83.5) 85.3 (78.8–91.8)# 77.9 (64.3–91.5)#
HES 83.2 (76.9–89.4) 65.8 (56.2–75.3) 93.1 (81.1–105.1) 84.7 (64.4–104.9)#
GELO 78.3 (63.2–93.3) 72.0 (66.9–77.1) 111.1 (84.0–138.2)&,* 113.0 (82.0–144.0)&,*,+
ESTIMATED PLATELET COUNT (X109/L−1)
FWB 144.0 (122.6–165.4) 131.3 (74.6–187.9) 127.5 (94.9–160.1) 144.0 (91.7–196.3)
CRYST 126.8 (95.5–158.0) 112.5 (91.8–133.2) 67.9 (21.5–114.3) 78.3 (60.0–96.5)
HES 133.8 (110.7–156.8) 115.1 (65.7–164.6) 104.3 (67.9–140.6) 88.3 (50.7–125.8)
GELO 134.3 (113.1–155.4) 117.0 (105.5–128.5) 135.5 (94.4–176.6) 105.8 (76.3–135.2)
Fluid was delivered directly after shock time point.
&Significantly different to FWB; *Significantly different to CRYST; +Significantly different to HES; #Significantly different to GELO (Bonferroni–Holm corrected P-value < 0.05).
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TABLE 2 | Rotational thromboelastometry parameters (mean, 95% confidence interval) in dogs (n = 6 per group) with hemorrhagic shock given 20mL kg−1 of either
fresh whole blood (FWB), hydroxyethyl starch 130/0.4 (HES), 4% succinylated gelatin (GELO), or 80mL kg−1 of balanced isotonic crystalloid (CRYST).
Parameter Baseline Shock T60 T180
INTEM CT (SEC)
FWB 279.3 (137.5–421.2) 204.8 (123.1–286.5) 330.5 (17.2–643.8) 269.0 (150.7–387.3)
CRYST 171.3 (149.1–193.5) 160.7 (129.2–192.1) 162.2 (134.0–190.3) 159.8 (142.8–176.9)
HES 201.2 (129.1–273.2) 145.8 (72.2–219.5) 231.8 (130.4–333.3) 199.0 (113.0–285.0)
GELO 221.5 (146.0–297.0) 161.0 (117.0–205.0) 224.3 (108.6–340.1) 193.5 (146.5–240.5)
INTEM CFT (SEC)
FWB 224.2 (143.1–305.2) 260.3 (180.6–340.0) 303.8 (102.0–505.7) 235.3 (178.9–291.8)
CRYST 143.5 (119.1–167.9) 227.8 (190.9–264.8) 298.8 (269.5–328.1) 234.5 (207.6–261.4)
HES 202.8 (106.9–298.8) 264.0 (168.0–360.0) 431.5 (287.3–575.7) 309.2 (221.0–397.3)
GELO 178.2 (128.4–227.9) 186.2 (114.2–258.1) 305.5 (211.1–399.9) 278.7 (178.1–379.2)
INTEM α (◦)
FWB 54.2 (44.9–63.4) 54.0 (46.3–61.7) 52.7 (38.5–66.8) 56.2 (49.8–62.6)
CRYST 68.0 (65.4–70.6) 62.7 (57.2–68.1) 56.8 (53.7–60.0) 60.7 (59.8–61.5)
HES 60.5 (49.4–71.6) 56.0 (46.5–65.5) 50.7 (40.2–61.1) 53.5 (46.4–60.6)
GELO 61.2 (56.5–65.9) 61.7 (53.8–69.6) 53.0 (46.7–59.3) 56.2 (49.8–62.6)
INTEM MCF (mm)
FWB 51.2 (46.9–55.4) 47.7 (43.0–52.3) 45.3 (38.3–52.3)+ 48.2 (44.5–51.8)+
CRYST 54.2 (50.8–57.5) 46.3 (43.0–49.7) 42.2 (39.9–44.4) 44.0 (41.4–46.6)
HES 50.3 (45.3–55.4) 44.5 (40.3–48.7) 37.0 (31.6–42.4)& 41.0 (36.2–45.8)&
GELO 54.0 (48.3–59.7) 51.2 (45.8–56.5) 41.5 (36.0–47.0) 42.8 (37.2–48.5)
INTEM LI60 (%)
FWB 99.0 (97.4–100.6) 99.7 (98.8–100.5) 99.7 (98.8–100.5) 99.2 (97.9–100.4)
CRYST 99.7 (98.8–100.5) 98.7 (97.6–99.8) 96.8 (94.7–99.0) 97.2 (94.4–99.9)
HES 99.2 (97.9–100.4) 98.5 (96.4–100.6) 87.8 (67.3–108.4) 90.0 (74.1–105.9)
GELO 99.5 (98.6–100.4) 99.7 (99.1–100.2) 98.3 (94.0–102.6) 96.5 (87.5–105.5)
EXTEM CT (SEC)
FWB 52.5 (40.8–64.2) 75.2 (57.2–93.1) 64.7 (45.3–84.1)+ 62.0 (53.1–70.9)
CRYST 54.8 (37.8–71.9) 66.2 (59.4–72.9) 72.8 (62.9–82.8)+ 71.5 (58.7–84.3)
HES 61.8 (40.6–83.0) 69.0 (56.1–81.9) 119.3 (57.4–181.3)&,*,# 82.7 (50.6–114.8)
GELO 47.8 (28.6–67.0) 55.8 (36.1–75.6) 76.2 (27.5–124.8)+ 75.2 (50.6–99.8)
EXTEM CFT (SEC)
FWB 178.2 (121.5–234.8) 217.3 (149.5–285.2) 251.0 (127.6–374.4) 202.2 (148.5–255.9)
CRYST 129.3 (115.4–143.3) 184.2 (152.6–215.7) 246.0 (198.3–293.7) 221.0 (177.7–264.3)
HES 145.3 (55.3–235.4) 208.0 (137.8–278.2) 373.4 (179.9–566.9) 437.3 (0.0–918.6)
GELO 139.3 (102.6–176.1) 165.0 (115.5–214.5) 230.4 (167.7–293.1) 263.3 (174.5–352.1)
EXTEM α (◦)
FWB 59.8 (53.5–66.1) 60.0 (55.9–64.1) 55.8 (48.8–62.9) 58.3 (54.4–62.3)
CRYST 66.5 (64.4–68.6) 63.3 (60.9–65.8) 59.3 (54.2–64.5) 60.8 (59.0–62.6)
HES 61.7 (55.1–68.2) 61.8 (56.4–67.2) 46.2 (28.6–63.8) 53.0 (39.8–66.2)
GELO 65.7 (62.8–68.5) 63.5 (59.9–67.1) 49.5 (32.7–66.3) 56.0 (52.5–59.5)
EXTEM MCF (mm)
FWB 50.5 (46.3–54.7) 44.7 (39.6–49.7) 45.3 (38.6–52.1)+ 47.0 (43.4–50.6)
CRYST 54.7 (52.1–57.2) 45.7 (42.1–49.3) 39.0 (33.3–44.7) 39.3 (34.7–44.0)
HES 49.3 (42.7–55.9) 42.5 (33.4–51.6) 31.2 (20.5–41.9)& 37.8 (28.6–47.1)
GELO 54.3 (47.8–60.8) 50.0 (43.4–56.6)ß 39.0 (26.6–51.4) 40.3 (31.9–48.8)
EXTEM TPI
FWB 18.8 (12.7–25.0) 12.5 (6.7–18.3) 12.3 (5.6–19.0) 14.0 (9.6–18.4)
CRYST 28.5 (22.8–34.2) 14.3 (10.5–18.2) 8.2 (5.6–10.8) 9.3 (6.1–12.6)
(Continued)
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TABLE 2 | Continued
Parameter Baseline Shock T60 T180
HES 20.2 (7.4–32.9) 14.2 (1.1–27.3) 4.8 (2.0–7.6) 8.2 (1.4–14.9)
GELO 28.8 (15.3–42.4) 21.0 (10.3–31.7) 11.2 (5.3–17.1) 9.5 (4.2–14.8)
EXTEM LI60 (%)
FWB 89.3 (66.9–111.7) 78.7 (48.1–109.3) 90.7 (70.7–110.7) 91.0 (78.2–103.8)
CRYST 99.0 (97.9–100.1) 87.7 (73.0–102.3) 84.7 (52.9–116.5) 78.8 (58.5–99.2)
HES 98.3 (95.5–101.2) 83.3 (56.1–110.6) 74.3 (36.5–112.2) 84.3 (56.2–112.5)
GELO 97.5 (93.8–101.2) 86.7 (65.3–108.1) 75.8 (49.2–102.5) 72.5 (42.5–102.5)
FIBTEM MCF (mm)
FWB 4.3 (3.5–5.2) 3.5 (2.4–4.6) 3.3 (1.5–5.2) 2.8 (1.0–4.6)
CRYST 6.0 (3.1–8.9) 4.7 (1.9–7.5) 2.8 (1.0–4.6) 3.2 (1.2–5.1)
HES 5.0 (2.6–7.4) 2.0 (0.0–4.9) 0.7 (0.0–2.4) 2.2 (0.0–5.2)
GELO 4.8 (3.3–6.4) 3.8 (2.3–5.4) 2.0 (0.2–3.8) 2.7 (1.1–4.2)
Fluid was delivered directly after shock time point.
&Significantly different to FWB; *Significantly different to CRYST; +Significantly different to HES; #Significantly different to GELO (Bonferroni–Holm corrected P-value<0.05). α, alpha
angle; CFT, clot formation time; CT, clotting time; LI60, lysis index at 60min; MCF, maximum clot firmness; TPI, thrombodynamic potential index.
TABLE 3 | Hyperfibrinolysis scores in dogs (n = 6 per group) with hemorrhagic
shock given 20mL kg−1 of either fresh whole blood (FWB), hydroxyethyl starch
130/0.4 (HES), 4% succinylated gelatin (GELO), or 80mL kg−1 of balanced
isotonic crystalloid (CRYST).
Group Baseline Shock T60 T180
HES 6, 0, 0, 0 4, 1, 1, 0 3, 1, 2, 0 4, 1, 1, 0
GELO 6, 0, 0, 0 4, 2, 0, 0 2, 3, 1, 0 3, 1, 2, 0
FWB 5, 0, 1, 0 3, 0, 2, 1 4, 0, 1, 1 4, 1, 1, 0
CRYST 6, 0, 0, 0 4, 1, 1, 0 4, 0, 2, 0 2, 1, 3, 0
P-value* 1.00 0.83 0.50 0.97
Fluid was delivered directly after shock time point. Data represent the number of dogs
assigned to the categories of no hyperfibrinolysis, reversible hyperfibrinolysis, irreversible
hyperfibrinolysis, or paradoxical increase in hyperfibrinolysis, respectively.
*Fisher’s exact test.
differences were beyond the effects of hemodilution, as indicated
by no significant differences in hemoglobin concentration or
platelet count between the HES, GELO, and CRYST groups.
As a secondary objective, this study also provides evidence
of hypocoagulability and platelet hyperreactivity in dogs with
atraumatic hemorrhagic shock.
Dogs administered HES in our study showed evidence
of hypocoagulability beyond hemodilution on ROTEM, most
notably having a longer EXTEM CT compared with all other
groups. A similar prolongation of EXTEM CT was seen in a
previous in vitro study where canine blood was diluted with
HES 130/0.4 (16). EXTEM CT is primarily affected by extrinsic
and common pathway coagulation factors (31). However, no
difference was detected in FVII between HES, GELO, and
CRYST, and other coagulation tests involving the common
pathway, such as INTEM CT, PT, and APTT, did not appear
to be affected to the same extent. Therefore, the mechanism of
the prolongation of EXTEM CT is unclear. The INTEM and
EXTEM MCF were also lower with HES, compared with FWB,
similar to when canine blood was diluted with HES 130/0.4
in vitro (16). INTEM and EXTEM MCF are primarily affected
by platelet function, functional fibrinogen and factor XIII (31,
32). Fibrinogen concentration was significantly lower in HES,
compared with FWB, which likely contributed.
The changes in EXTEM CT, INTEM MCF, and EXTEM
MCF with HES at T60 were beyond the limits of our canine
institutional reference intervals (EXTEM CT: 30–94 s, INTEM
MCF: 42–67mm, EXTEM MCF: 42–70mm), however the
clinical relevance of these abnormalities in dogs is unknown.
Also, note that our institutional reference intervals were
established with venous blood from conscious non-greyhound
dogs. Prolongation of EXTEM CT is predictive of hemorrhage
in humans undergoing liver transplantation (33). Reduction in
MCF is predictive of blood loss and transfusion requirements
in human trauma and surgical patients (34–36). In dogs,
EXTEM CT was longer and EXTEM MCF was lower in cases
that had hemorrhage, compared to those that did not, with
Angiostrongylus vasorum infection (37) and leptospirosis (38).
Therefore, the effect of HES on coagulation may contribute to
risk of hemorrhage in the dog. Clinical studies are needed to
further characterize coagulation dysfunction with HES 130/0.4 in
the dog. However, it is prudent to use HES with caution in dogs
at risk of significant hemorrhage, and evaluation of coagulation
using viscoelastic tests should be considered in dogs showing
clinical signs of hemorrhage following HES administration.
There was evidence of impaired platelet function following
GELO administration in our study, as measured by a higher
PCT. This has not been previously reported in dogs. In humans,
GELO has been associated with prolongation of bleeding time
(39) and PCT (40), decreased integrin αIIbβ3 activity (40) and
decreased ristocetin-stimulated platelet aggregation (39, 41). Pigs
administered GELO showed decreased aggregation on collagen-
stimulated impedance aggregometry (42). Binding of GELO
molecules to the platelet surface, including receptors such as
integrin αIIbβ3, is a potential mechanism. In our study,mean PCT
in the GELO group was prolonged beyond our non-greyhound
canine institutional reference interval (52–101 s), as well as the
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TABLE 4 | Plasma coagulation assay parameters (mean, 95% confidence interval) in dogs (n = 6 per group) with hemorrhagic shock given 20mL kg−1 of either fresh
whole blood (FWB), hydroxyethyl starch 130/0.4 (HES), 4% succinylated gelatin (GELO), or 80mL kg−1 of balanced isotonic crystalloid (CRYST).
Parameter Baseline Shock T60 T180
PROTHROMBIN TIME (SEC)
FWB 7.5 (7.2–7.7) 8.4 (7.9–8.9) 8.3 (7.8–8.8)*,+,# 8.5 (8.1–8.9)*,+,#
CRYST 7.4 (7.2–7.7) 8.5 (8.1–8.8) 11.4 (10.2–12.7)& 10.3 (9.6–11.0)&
HES 7.8 (7.2–8.3) 8.9 (7.6–10.2) 12.0 (9.4–14.7)&,# 10.3 (8.9–11.8)&
GELO 7.4 (6.9–7.9) 8.1 (7.7–8.5) 10.6 (9.5–11.6)&,+ 10.2 (9.2–11.1)&
ACTIVATED PARTIAL THROMBOPLASTIN TIME (SEC)
FWB 15.2 (13.5–16.9) 14.2 (12.2–16.1) 14.8 (12.9–16.6)*,+,# 14.8 (13.6–16.0)+
CRYST 15.4 (14.1–16.6) 14.7 (12.3–17.0) 23.5 (18.2–28.8)& 18.8 (14.7–22.8)
HES 16.0 (14.1–17.8) 14.5 (12.2–16.8) 25.6 (21.0–30.1)&,# 19.8 (16.7–22.9)&
GELO 15.2 (14.1–16.3) 14.1 (12.8–15.4) 21.0 (16.5–25.5)&,+ 18.5 (16.7–20.2)
FIBRINOGEN CONCENTRATION (g/L−1)
FWB 1.33 (1.07–1.59) 0.93 (0.73–1.13) 0.99 (0.80–1.19)*,+, # 0.93 (0.74–1.12)
CRYST 1.41 (1.19–1.62) 0.93 (0.76–1.09) 0.52 (0.42–0.62)& 0.60 (0.46–0.74)
HES 1.42 (1.02–1.81) 0.94 (0.58–1.29) 0.51 (0.33–0.69)& 0.64 (0.46–0.82)
GELO 1.51 (1.16–1.85) 1.11 (0.82–1.39) 0.64 (0.42–0.87)& 0.67 (0.41–0.93)
FACTOR VII ACTIVITY (%)
FWB 102.6 (87.9–117.4) 79.9 (66.7–93.1) 78.8 (70.7–87.0)*,+, # 72.5 (63.9–81.1)+,#
CRYST 108.5 (87.6–129.4) 83.8 (65.1–102.5) 55.3 (42.8–67.7)& 62.6 (45.4–79.8)
HES 90.2 (77.1–103.3) 70.1 (52.7–87.5) 45.3 (34.6–56.1)& 50.7 (39.9–61.5)&
GELO 95.1 (83.0–107.3) 77.5 (66.3–88.7) 53.0 (45.2–60.8)& 52.6 (43.5–61.7)&
FACTOR VIII ACTIVITY (%)
FWB 127.5 (86.9–168.2) 153.2 (131.8–174.6) 138.6 (110.6–166.6)*,+, # 117.4 (106.4–128.3)
CRYST 108.8 (81.8–135.9) 169.0 (121.8–216.3) 71.2 (54.9–87.4)& 93.6 (64.9–122.2)
HES 93.8 (77.8–109.9) 162.0 (107.5–216.5) 75.4 (61.1–89.7)& 83.3 (66.5–100.1)
GELO 109.1 (85.2–133.0) 137.5 (116.4–158.6) 83.3 (56.3–110.3)& 86.3 (66.0–106.6)
VON WILLEBRAND FACTOR ANTIGEN (%)
FWB 103.5 (77.0–130.0) 71.8 (35.0–108.5) 96.7 (64.8–128.6)*,+, # 82.1 (44.3–120.0)
CRYST 102.5 (74.2–130.7) 86.7 (46.6–126.9) 42.2 (31.9–52.4)& 48.5 (30.2–66.8)
HES 91.5 (78.5–104.5) 61.6 (30.2–93.1) 47.1 (33.4–60.9)& 51.8 (34.3–69.3)
GELO 105.1 (67.5–142.7) 77.0 (41.8–112.2) 53.9 (35.8–72.0)& 41.8 (19.9–63.8)
Fluid was delivered directly after shock time point.
&Significantly different to FWB; *Significantly different to CRYST; +Significantly different to HES; #Significantly different to GELO (Bonferroni–Holm corrected P-value < 0.05).
published reference interval in greyhounds (43). The clinical
relevance of PCT prolongation in dogs is not fully known,
however there is a weak correlation between PCT and clinical
bleeding in dogs with congenital von Willebrand Disease (44).
Clinical studies to assess risk of hemorrhage in dogs treated with
GELO are needed, andGELO should be used with caution in dogs
at risk of significant hemorrhage or with other disturbances of
coagulation. Conversely, HES did not show evidence of platelet
dysfunction in our study. This is similar to a previous greyhound
hemorrhagic shock model (10) but differs from a conscious
healthy dog study that used HES 670/0.75 (18). Hydroxyethyl
starch products with lower MW and degree of substitution have
less effect on platelet function in vitro in dog blood (13) and
in vivo in people (45). Clinical studies are needed to further
evaluate platelet dysfunction with HES 130/0.4 in the dog, as this
may be affected by dose, duration of therapy and comorbidities,
however this study does not support clinically relevant platelet
antagonism.
A secondary exploratory objective of this study was to assess
coagulation before and after hemorrhagic shock in all subjects.
There was evidence of platelet hyperreactivity with hemorrhagic
shock in our study, with a significant decrease in PCT. A similar
decrease in PCT that was not statistically significant was seen
in a previous greyhound hemorrhagic shock model study (27),
where the lack of significance was postulated to be a type 2
error due to the small sample size. In contrast, another canine
hemorrhagic shock model study (9) in beagles showed decreased
platelet function, as measured by impedance aggregometry. The
different findings may reflect differences between PCT and
aggregometry, differences between breeds of dog or differences
in the severity and duration of shock, with more severe
hypotension seen in the latter study. In one study of people
with significant intraoperative hemorrhage, platelet function
measured by impedance aggregometry initially decreased, then
increased above baseline (46), suggesting duration of shock
may affect platelet activation. Results of ROTEM and plasma
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TABLE 5 | Platelet closure time and count, rotational thromboelastometry, and plasma coagulation assay parameters (mean, 95% confidence interval) in dogs (n = 24)
with hemorrhagic shock.
Parameter Baseline Shock P value*
Platelet Closure Time (sec) 83.4 (77.6–89.1) 69.0 (65.2–72.8) <0.001
Estimated Platelet Count (x109/L−1) 134.3 (124.7–143.9) 119.4 (106.3–132.5) 0.057
INTEM CT (sec) 218.3 (180.9–255.7) 168.1 (143.2–193.0) <0.001
INTEM CFT (sec) 187.2 (158.3–216.0) 234.6 (203.6–265.6) <0.001
INTEM α (◦) 61.0 (57.4–64.5) 58.6 (55.3–61.9) 0.067
INTEM MCF (mm) 52.4 (50.5–54.3) 47.4 (45.4–49.4) <0.001
INTEM LI60 (%) 99.3 (98.9–99.8) 99.1 (98.6–99.7) 0.458
EXTEM CT (sec) 54.3 (47.3–61.2) 66.5 (60.1–73.0) <0.001
EXTEM CFT (sec) 148.0 (125.3–170.7) 193.6 (170.5–216.8) <0.001
EXTEM α (◦) 63.4 (61.2–65.6) 62.2 (60.5–63.8) 0.117
EXTEM MCF (mm) 52.2 (50.0–54.4) 45.7 (43.0–48.4) <0.001
EXTEM LI60 (%) 96.0 (91.4–100.7) 84.1 (74.9–93.3) 0.002
EXTEM TPI 24.1 (19.8–28.4) 15.5 (11.8–19.2) <0.001
FIBTEM MCF (mm) 5.0 (4.2–5.9) 3.5 (2.6–4.4) <0.001
Prothrombin time (sec) 7.5 (7.3–7.7) 8.5 (8.2–8.8) <0.001
Activated partial thromboplastin time (sec) 15.4 (14.8–16.0) 14.4 (13.6–15.1) <0.001
Fibrinogen concentration (g/L−1) 1.41 (1.29–1.54) 0.97 (0.87–1.08) <0.001
Factor VII activity (%) 99.1 (92.5–105.7) 77.8 (71.7–84.0) <0.001
Factor VIII activity (%) 109.8 (98.0–121.6) 155.4 (139.9–171.0) <0.001
von Willebrand factor antigen (%) 100.6 (90.0–111.3) 74.3 (60.2–88.4) <0.001
*Paired t–test, bold indicates P < 0.05. α, alpha angle; CFT, clot formation time; CT, clotting time; LI60, lysis index at 60 minutes; MCF, maximum clot firmness; TPI, thrombodynamic
potential index.
coagulation assays showed evidence of decreased coagulation
factor activity, delayed clot formation, impaired clot strength
and increased fibrinolysis during hemorrhagic shock. There were
also some markers of hypercoagulability, notably decreases in
INTEM CT and APTT and an increase in FVIII, highlighting
the complexity of coagulopathy in shock. These findings were
more pronounced than a previous canine hemorrhagic shock
model (9), which may be due to a larger sample size in the
current study, differences between breeds of dog or differences
in the severity and duration of shock. Our findings were
similar to dogs with spontaneous hemoperitoneum (8), which
were also hypocoagulable and hyperfibrinolytic. There were
also similarities with some studies of dogs with traumatic
hemorrhagic shock (6, 7), however it should be noted that
traumatic hemorrhagic shock may differ from atraumatic
hemorrhagic shock due to injury-induced endothelial activation,
auto-heparinization and inflammation (47). Also, the dogs in this
study were under general anesthesia and receiving continuous
crystalloid infusion, which may have also altered coagulation.
Larger clinical studies of coagulation impairment in dogs with
naturally-occurring hemorrhagic shock are needed.
The major limitation of our study was the use of ex-
racing greyhounds, which are not purpose-bred or housed
in a laboratory environment. These dogs were unable to be
rehomed and were donated for blood product collection for
clinical use, anatomy cadaver teaching and other research.
Their use in research immediately before euthanasia obviates
procurement of other large animals purely for research purposes.
Greyhounds are known to have differences in coagulation
compared with other breeds (48), notably including a syndrome
of delayed postoperative bleeding that may be due to excessive
fibrinolysis (49, 50). Interestingly, in our study there was
minimal evidence of hyperfibrinolysis, based on ROTEM LI60.
However, there is little published data on how to interpret
fibrinolysis parameters on standard viscoelastic tests in the
dog (28). Previous studies using thromboelastography have also
failed to show differences in fibrinolysis parameters between
greyhounds and other dog breeds (48). In our study the mean
FIBTEM MCF at baseline was 5.0mm, which is below the
previously published normal reference interval for dogs (16).
Whilst breed differences may have impacted the absolute results
of this study, our primary objective was to compare the effects
of different fluids, and the relative changes are still highly
relevant. Most studies of coagulation use venous blood, however
arterial blood was used in this study for practical reasons.
The clinical relevance of alterations in ROTEM parameters
is not fully understood. Finally, our study was limited by
sample size, which may have contributed to type 2 error
and lack of finding further differences. Insufficient data was
available for power calculation for many of the parameters
tested.
CONCLUSION
Our study showed that in dogs with hemorrhagic shock,
volume replacement with FWB was associated with the least
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impairment of coagulation compared with HES, GELO, and
CRYST. Both GELO and HES impaired coagulation beyond
the effects of hemodilution, with GELO showing impaired
platelet function and HES showing hypocoagulable ROTEM and
plasma coagulation assays. Clinical trials to assess the risk of
coagulation impairment and bleeding in dogs with naturally-
occurring hemorrhagic shock treated with synthetic colloids
are needed. Our study provides evidence that HES and GELO
should be used with caution in dogs at risk of significant
hemorrhage.
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